Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Southwest Synthetic Pharmaceutical Restructures

This article was originally published in PharmAsia News

Executive Summary

Southwest Synthetic Pharmaceutical will issue 41 million shares to Peking University International Hospital to acquire the latter's 90.63 percent stake in Chongqing Daxin Pharmaceutical at 5.36 yuan per share. After the equity issuance estimated at 220 million yuan, Peking University International Hospital will hold 50.50 percent of Southwest Synthetic's total shares. Chongqing Daxin's major products are Lovastatin, Mycophenolic Acid, Tobramycin and Amikacin Sulfate, which are mainly exported to overseas markets. Recognized globally for its quality and standards, the firm will represent a strong asset to Southwest Synthetic. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts